Understanding how a specific enzyme affects the metabolism of diclofenac

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to investigate the role of the enzyme UDP-glucuronosyltransferase (UGT) 2B17 in the metabolism of diclofenac, a commonly used anti-inflammatory medication. The study will also examine how curcumin, a natural product and UGT2B17 inhibitor, influences the pharmacokinetics of diclofenac. By analyzing the genetic variations of UGT2B17 and their impact on drug metabolism, the research seeks to provide insights that could inform future studies on the safety and efficacy of diclofenac and other drugs metabolized by UGT2B17. Participants will be healthy adults aged 18-64 who meet specific eligibility criteria and will undergo controlled interventions involving diclofenac and curcumin.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged from 18-64 years and healthy
* Not taking any medications (prescription and non-prescription) or dietary/herbal supplements known to alter the pharmacokinetics of diclofenac or curcumin
* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of the first day of each study arm
* Willing to abstain from consuming any alcoholic beverages for one day prior to any study day, during the 14-hour inpatient days, and for the outpatient visit(s) following the 14-hour days
* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms)
* Have the time to participate
* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study

Exclusion Criteria:

* Under the age of 18 or over the age of 65 years
* Smoke/vape/chew tobacco products
* Use cannabis products, including marijuana, hemp, and other THC- or CBD-containing products
* Have any current major illness or chronic illness such as (but not limited to) kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV/AIDS
* History of anemia or any other significant hematologic disorder
* History of drug or alcohol addiction or major psychiatric illness
* Pregnant or nursing or plan to become pregnant within 3 weeks after participation
* History of allergy intolerance to diclofenac or curcumin
* Taking concomitant medications, both prescription and non-prescription (including dietary supplements/herbal products), known to alter the pharmacokinetics of diclofenac or curcumin
* Taking any turmeric spice or curcumin supplement
* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or quality of the data
* Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk

Where it's running

• Washington State University College of Pharmacy and Pharmaceutical Sciences
  Spokane, Washington, United States Recruiting

Study contacts

• Study coordinator: Mary F Paine, RPh, PhD
• Email: mary.paine@wsu.edu
• Phone: 509-358-7759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating how oregano affects drug metabolism

  This study is testing whether taking oregano supplements affects how the body processes certain medications in healthy adults.

  Recruiting Early Phase 1 Washington State University · Spokane, Washington · NCT06693960

• Effects of a hemp product on clopidogrel levels in the body

  This study is testing how different amounts of CBD from hemp affect the levels of the blood thinner clopidogrel in healthy adults aged 21-64.

  Recruiting Early Phase 1 Washington State University · Spokane, Washington · NCT06692933

• Pharmacist-guided medication management using pharmacogenomics to improve depression care

  This study tests whether pharmacists in community pharmacies can use a patient's pharmacogenomic results to guide antidepressant treatment and improve Depression outcomes compared with usual care.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07373470

• Preventing medication-related side effects and falls in older adults after an ER visit

  This project will test whether giving doctors patients' DNA results to guide prescribing can reduce medication side effects and falls in adults 65 and older who come to the emergency department after a ground-level fall.

  Recruiting Florida Atlantic University · Delray Beach, Florida · NCT07216846

• Using genetic testing to improve medication safety in hospitals

  This study is testing whether genetic testing can help doctors choose safer medications for hospitalized patients to reduce side effects and treatment failures.

  Recruiting at 4 sites NHS Greater Glasgow and Clyde · Clydebank and 4 other locations · NCT06907784

• Understanding how trihexyphenidyl works in children with dystonic cerebral palsy

  This study is testing how well the medication trihexyphenidyl works for children with dystonic cerebral palsy and if their genes affect how the drug works.

  Recruiting Phase 1 Children's Mercy Hospital Kansas City · Kansas City, Missouri · NCT06554288

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.